Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-04-11

Clinical Trial Update: Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Rituximab as maintenance therapy for marginal zone B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rituximab (rituximab)

Snippet

Sponsor: Dong-A University Hospital | Conditions: Lymphoma | Phase 2 | Status: COMPLETED